Moleculin Biotech, Inc. is a pre-clinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology.

Board of Directors

Robert-GeorgeRobert E. George

Mr. George was a partner with the international accounting firm of PricewaterhouseCoopers (PWC) for 27 years until 2010, where his client service sectors included healthcare, among others. Mr. George currently serves as Chairman of the Audit Committee for The University of Texas Health Science Center at Houston and, since June 2011, has been a member of The University of Texas at Austin, McCombs Graduate School of Business accounting faculty. Since January 2014, he also has been the Director of Energy Programs and Conferences for the Professional Development Institute. His past experience includes being an Editorial Advisor to the American Institute of Certified Public Accountants Journal of Accountancy and a contributing author for two accounting books. Mr. George graduated with accounting honors from the University of North Texas.

michael-cannonMichael D. Cannon

Between 1997 and 2004, Mr. Cannon was the Chief Science Officer, EVP and a Director of SICOR, Inc., a U.S. public pharmaceutical company, until its acquisition by Teva Pharmaceutical Industries, Inc. SICOR focused on generic finished dosage injectable pharmaceuticals, active pharmaceutical ingredients and generic biopharmaceuticals. While at SICOR, he oversaw the acquisition and development of the biological business, including initiation and management of international partnerships, as well as on the design, construction, and licensure of protein manufacturing facilities. From July 2005 to December 2009, Mr. Cannon was a member of the scientific advisory board of Trevi Health Ventures LP, a New York investment fund specializing in health care investments. From May 2005 until December 2011, Mr. Cannon was a partner in a private partnership formed to evaluate and perform preliminary development of intellectual property in the healthcare sector. Since 2005, Mr. Cannon has served as a board member for several private companies. Mr. Cannon currently serves on the board of directors of 4 privately held biotech companies, including 2 focused on cancer-related treatments, and has been a partner and advisor in several biotech venture firms. Mr. Cannon has a degree in chemistry from Fordham College.

John Climaco

Previously Mr. Climaco served as the Executive Vice President of Perma-Fix Medical S.A, a Polish subsidiary of Perma-Fix Environmental Services, Inc. (NASDAQ:PESI) where he also served as a director from 2013 to 2017. At Perma-Fix, Mr. Climaco managed the development of a novel method to produce Technitium-99, the most widely used medical radio-isotope in the world.  Mr. Climaco currently serves on the board of directors of Moleculin Biotech, Inc. (NASDAQ:MBRX), a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, Digirad Corporation (NASDAQ:DRAD), a leading manufacturer of cameras for nuclear imaging applications and a national provider of in-office nuclear cardiology imaging, and Birner Dental Management Services, Inc. (OTCQX Best Market: BDMS), the largest manager of dental practices in Colorado, New Mexico and Arizona.  Previously Mr. Climaco also served on the board of directors of PDI, Inc. (NASDAQ:PDII) a provider of outsourced commercial services to pharmaceutical, biotechnology, and healthcare companies, and InfuSystem Holdings, Inc. (NASDAQ:INFU), the largest supplier of infusion services to oncologists in the US.

From 2003 to 2012, Mr. Climaco served as President and Chief Executive Officer, as well as a member of the Board of Directors of Axial Biotech, Inc., a venture-backed molecular diagnostics company specializing in spine disorders, which he cofounded in 2003. Mr. Climaco played an instrumental role in bringing genomic medicine to the field of orthopaedics internationally. Under Mr. Climaco’s leadership, Axial Biotech successfully developed and commercialized ScoliScore, a clinically validated, polygenic test that provides a qualitative and quantitative assessment of the likelihood of spinal curve progression for children who have been diagnosed with adolescent idiopathic scoliosis. In the process of taking Axial from inception through product development to international commercialization, Mr. Climaco raised over $30MM in financing for the company. Mr. Climaco engineered and managed major strategic partnerships with international healthcare companies including Medtronic, Johnson & Johnson and Smith & Nephew. Among other accolades, Orthopaedics This Week magazine recognized ScoliScore as the Best New Diagnostics Technology for Spine Care, and The Chicago Tribune called ScoliScore “a crystal ball for the spine.” Mr. Climaco ultimately negotiated the sale of ScoliScore to TransGenomic (NASDAQ OTC: TBIO).

From 2001 to 2007, Mr. Climaco practiced law for the firm of Fabian and Clendenin, specializing in corporate and tax strategies for diverse clients across the U.S. and Europe, as well as joint venture, corporate and securities transactions. Mr. Climaco earned his B.A. in Philosophy from Middlebury College, Cum Laude, and holds a J.D. from the University of California Hasting College of the Law.

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates regarding Moleculin and breakthrough Cancer related innovations!

You have Successfully Subscribed!